Navigation Links
Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.

ESTERO, Fla., July 11, 2013 /PRNewswire/ -- On May 16, 2013, United States District Court for the Eastern District of North Carolina DISMISSED with prejudice all claims for copyright and patent infringement asserted by plaintiffs Cornerstone BioPharma, Inc. ("Cornerstone") and J-Med Pharmaceuticals, Inc. ("J-Med") against Vision Pharma, LLC ("Vision"), Sander Busman, Thomas DeStefano, and Michael McAloose.  The dismissal followed the decision of the United States Court of Appeals for the Federal Circuit, upholding the USPTO Board of Patent Appeals and Interferences' rejection of U.S. Patent No. 6,270,796, the sole patent asserted in the case. See In re J-Med Pharmaceuticals, Inc., No. 11-1415 (Fed. Cir.).  On January 11, 2013, the USPTO issued an Ex Parte Reexamination Certificate cancelling all claims of the '796 Patent.

"We were very confident from the absolute beginning that Vision, Thomas DeStefano, Michael McAloose and I would receive a most favorable outcome regarding Cornerstone and J-Med's case against us.  Although these results are especially pleasing, this decision should not have taken so long to happen," said Sander S. Busman, Founder, President & CEO, Vision Pharma. Vision Pharma was represented by Ben Pleune and David Alban of Alston & Bird, LLP. 

About Vision Pharma

Vision Pharma specializes in niche, generic pharmaceuticals with various delivery options and dosage forms.  The company provides quality products at competitive prices while improving the lives of those who take their medicines. The organization's customer service acts promptly to requests while continuously improving to fulfill each customer and patient need. Maintaining additional inventory ensures Vision's ability to provide increased service levels. The pipeline of generic pharmaceuticals planned to market continues to be a strong focus internally and with other pharmaceutical organizations, domestically and internationally. Valuable relationships that are built show true dedication to each partnering company. You can count on Vision Pharma to consider the patient's safety as a top priority when developing and manufacturing their items. To learn more, please visit

Media Relations Contact:
Sander S. Busman
Vision Pharma
Founder, President & CEO



SOURCE Vision Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
2. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
4. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
5. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
6. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Argus Announces Next Generation Pharmacy Claims Processing Solution
9. American Association for Homecare Expects Medicare to Move Past its Deny-at-All-Costs Culture that Routinely Denies Claims for Power Wheelchairs
10. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
11. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015 ... the "Orphan Drugs Market 2015-2019" report ... has announced the addition of the "Orphan ... --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to their ...
(Date:11/30/2015)... global cell culture market is expected ... bn by 2022 at a CAGR of 7.1% therein. --> ... its 2013 value of US$6.1 bn to US$11.3 bn by 2022 ... Research has announced the release of a new market research study, ... ,Cell Culture Market - Global Industry Analysis, Size, Share, Growth, Trends ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... According to an article published November 13th by People ... to show her Instagram followers that the praise that they were bestowing on her ... she didn’t “want to mislead any mommy's who just had babies and are stressing,” ...
(Date:11/30/2015)... ... ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks County ... Institute. , The institute, which is the research arm of the Hepatitis B Foundation, ... conference, which focused on ways companies can work to reduce the cost and improve ...
(Date:11/30/2015)... ... November 30, 2015 , ... At Grand Dental PC, their ... setting. , When you have dental problems, you need to turn to a dentist ... diagnose and treat your needs, a friendly dentist who counsels you on the best ...
(Date:11/30/2015)... ... , ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, ... Medicine in 1935. His father graduated from NYU School of Dentistry in 1965. ... as their commitment and passion to the Practice of Dentistry. Continuing the family ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
Breaking Medicine News(10 mins):